Lynne Marie Sullivan is CFO & Head of Corp. Dev. of Unity Biotechnology, Inc.. Currently has a direct ownership of 32,685 shares of UBX, which is worth approximately $42,817. The most recent transaction as insider was on Jun 25, 2024, when has been sold 324 shares (Common Stock, $0.0001 par value) at a price of $1.4 per share, resulting in proceeds of $453. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 32.7K
0.98% 3M change
0.98% 12M change
Total Value Held $42,817

Lynne Marie Sullivan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 25 2024
SELL
Open market or private sale
$453 $1.4 p/Share
324 Reduced 0.98%
32,685 Common Stock, $0.0001 ...
May 15 2022
BUY
Other acquisition or disposition
$6,373 $6.89 p/Share
925 Added 2.73%
33,009 Common Stock, $0.0001 ...
Feb 09 2022
BUY
Grant, award, or other acquisition
-
50,000 Added 13.27%
326,785 Common Stock, $0.0001 ...
Jun 24 2021
BUY
Grant, award, or other acquisition
-
30,833 Added 10.22%
270,833 Common Stock, $0.0001 ...

Also insider at

INZY
Inozyme Pharma, Inc. Healthcare
SLDB
Solid Biosciences Inc. Healthcare
PHGE
BiomX Inc. Healthcare
LMS

Lynne Marie Sullivan

CFO & Head of Corp. Dev.
Ness Ziona,, L3

Track Institutional and Insider Activities on UBX

Follow Unity Biotechnology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells UBX shares.

Notify only if

Insider Trading

Get notified when an Unity Biotechnology, Inc. insider buys or sells UBX shares.

Notify only if

News

Receive news related to Unity Biotechnology, Inc.

Track Activities on UBX